Results: The methodology differentiated blood and bone marrow CMML cases from non-CMML + non-aCML but not three aCML cases in the clinical

Conclusions: Quantification of monocyte subsets is useful in clinical practice as a diagnostic marker of CMML in blood and bone marrow specimens. The percentage of nonclassical monocytes should be included in analysis of monocyte subsets.
Over the past 30 years, the diagnosis of hematologic malignancies has shifted from being based almost exclusively on morphology and clinical data to include flow cytometry, cytogenetics, and molecular genetics. According to the 2016 revision to the World Health Organization guidelines, the diagnostic criteria for chronic myelomonocytic leukemia (CMML), a myelodysplastic/myeloproliferative neoplasm (MDS/MPN), includes persistent monocytosis (≥1 × 10 9 /L and 10% of leukocytes), the lack of satisfying the criteria for any other myeloproliferative neoplasm, the lack of both translocations involving PDGFRA, PDGFRB, and FGFR1 and the PCM1-JAK2 translocation, less than 20% blasts, and either myelodysplasia, an acquired clonal cytogenetic, or molecular genetic abnormality in hematopoetic cells, and the exclusion of other causes of monocytosis, with flow cytometry playing no role in the diagnosis. showed that there is an increased accumulation of the MO1 subset in the peripheral blood of CMML patients compared to both healthy controls and patients with other hematologic malignancies. Specifically, it was determined that a cutoff value of greater than 94% MO1s could be utilized to differentiate CMML cases. This increase in MO1% was correlated with both an increase in the total number of MO1s and a decrease in the number of MO3s. 2 Similarly, it was found that this increase in MO1s can differentiate CMML from MDS 3 and MPN 4 and can predict the subset of MDS cases that evolve into CMML. 5 While this method shows robust ability to discriminate CMML patients from others, the published method required the collection of 50,000 events in the monocyte gate. As the collection of 50,000 to 100,000 total events is often used as the stopping point for standard clinical flow cytometric analyses, the collection of 50,000 monocytic events would necessitate a different stopping parameter, which is not ideal for a screening test that is part of a laboratory's standard flow cytometry panel. Also, most research has focused on the increased MO1 subset with the decreased MO3 subset receiving little interest.
Herein, we show that, with key modifications, this methodology robustly differentiates CMML cases from non-CMML + nonatypical chronic myeloid leukemia (aCML) but not the three aCML cases in the clinical setting.
Materials and Methods
Patients and Samples
Peripheral blood and bone marrow aspirate samples were collected in EDTA tubes. From March 2016 to May 2017, per clinical practice at the University of Rochester Medical Center Flow Cytometry Laboratory, 102 cases (77 peripheral blood specimens, 27 bone marrow specimens) in which there was a possibility of CMML or aCML (including known cases of CMML or aCML, cases with a monocytosis, cases in which CMML and/or aCML was in a clinical differential, and cases flagged as suspicious upon initial smear review) were subjected to monocyte subset screening by flow cytometry. Of these cases, all those in which sufficient clinical information was available for a diagnosis of CMML to be rendered were included in this study (68 blood cases, 25 bone marrow cases). Cases of aCML (three bone marrow cases), another MDS/MPN neoplasm, were grouped separately from both CMML and other (non-CMML + nonaCML) cases. For the purposes of this study, a case was classified as CMML if there was a previous or subsequent diagnosis of CMML, the case met diagnostic criteria for CMML, or, in cases in which a confirmatory bone marrow and cytogenetic studies were not done, there was definitive dysplasia in the myeloid lineage on peripheral smear along with a monocytosis. All procedures followed local institutional review board policy.
Flow Cytometry
Flow cytometry was performed on peripheral blood and bone marrow aspirate samples as follows. Two tubes were run for all samples, an experimental tube with the following antibodies, fluorescein isothiocyanate (FITC) anti-CD16 (clone 3G8), phycoerythrin (PE) anti-CD64 (clone 10.1), peridinin chlorophyll protein complexcyanine (PerCP-Cy) 5.5 anti-CD33 (clone P67-6), PE-Cy7 anti-CD56 (clone NCAM16.2), allophycocyanin (APC) anti-CD14 (clone MϕP9), and APC-H7 anti-CD45 (clone 2D1), and a control tube with the appropriate isotype controls (all antibodies from BD Biosciences, San Jose, CA). Whole blood samples were stained and RBCs were then lysed with BD FACSlyse. After washing with 1× phosphate-buffered saline, flow cytometric acquisition was performed with a FACSCanto flow cytometer (BD Biosciences), with 50,000 total events collected for each specimen. Analysis was performed with FlowJo version 10 software (FlowJo, Ashland, OR). Briefly, after the exclusion of doublets and small noncellular events, the monocyte gate was determined based on a CD45 vs side scatter plot (mature monocytes in bone marrow specimens). Next, as in Selimoglu-Buet et al,
-cells were excluded (for both concordance with the MO1/MO2/MO3 paradigm as well as the exclusion of CD14 dim/-/CD16 -immature monocytes in bone marrow specimens), 6 and the resulting population was assessed for CD14 and CD16 expression as well as for the aberrant monocytic marker CD56. Cutoff values for CD16 expression were based on the CD16 positive and negative populations seen in the lymphocyte gate (see Results).
Statistical Analysis
All statistical analyses were done with SigmaPlot for Windows version 14.0 (Systat Software, San Jose, CA). ANOVA was used to compare groups. For twoway ANOVA comparisons, specimen type and diagnosis (CMML vs non-CMML + non-aCML) were used as factors. Receiver operator characteristic (ROC) curves were obtained utilizing CMML as the positive state. P less than .05 was considered significant.
Results
Case Distribution
Of the 68 peripheral blood specimens, 16 specimens were categorized as CMML ❚Table 1❚. The 52 non-CMML + non-aCML blood cases were subcategorized as follows: six MPN, two acute myeloid leukemias, eight clonal circulating B or T-cell proliferations with a monocytosis (clonal B/T), four cases of solid tumors (carcinoma or lymphoma) with a monocytosis, and 32 cases best characterized as other/reactive. Within the bone marrow cases, 10 were categorized as CMML, three aCML, and 12 non-CMML + non-aCML (three MPN, three cases of CMML or aCML posttreatment [posttreatment CMML cases have been shown to have normalization of monocyte subsets 2 ], one case of lymphoma with a monocytosis, and five other/reactive). ❚Figure 1❚ displays the total number of singlet-gated events, monocyte gate events, and lymphocyte gate events analyzed for the cases. 
Verification of Classical Monocyte Percentage in Differentiating CMML Cases
To determine if the expression of CD14 and CD16 on monocytes could differentiate CMML cases in our hands, we first looked at MO1%. The gating strategy for determination of the monocyte subsets and representative dot plots are shown in ❚Figure 2❚. Findings were substantially different between specimen types, therefore blood and bone marrow cases were analyzed separately. There was a significant difference in MO1% between CMML and non-CMML + non-aCML blood cases (94.9% ± 6.9% vs 85.9% ± 7.0%, P < .001), with subgroup analysis showing the MPN, clonal B/T, and other/reactive subgroups were significantly different from CMML ❚Figure 3A❚. Similar findings were observed among the bone marrow specimens with the exception that the three aCML cases showed no apparent difference in MO1% compared to the CMML cases (all three >95%) ❚Figure 3B❚. In all, while MO1% was significantly different between CMML and non-CMML + non-aCML, there was a distinct subset of CMML cases (two blood, two bone marrow) that had an MO1% considerably less than 94%, the cutoff established by Selimoglu-Buet et al 2 ❚Figure 3C❚.
Measurement of Nonclassical and Intermediate Monocyte Percentages
To determine if measuring other monocyte subsets led to greater homogeneity amongst CMML cases, we examined the nonclassical monocyte percentage (MO3%) in CMML vs non-CMML + non-aCML. There was a significant difference in MO3% amongst the peripheral blood specimens, with CMML having a significantly lower percentage than non-CMML + non-aCML (0.5% ± 0.3% vs 5.8% ± 4.4%, P < .001), and subgroup analysis showing significant differences between CMML and the clonal B/T and other/reactive groups ❚Figure 4A❚. CMML bone marrow cases also had a significantly lower MO3% than non-CMML + nonaCML (1.1% ± 0.5% vs 10.7% ± 8.6%, P = .002). As with MO1%, there was no apparent difference in MO3% percentage between CMML and the three aCML cases ❚Figure 4B❚. While there was substantial overlap between groups and high variance within groups, a statistically significant difference was also found in the percentage of intermediate monocytes (MO2%) in peripheral blood specimens, with the CMML cases having a decreased percentage compared to non-CMML + non-aCML (4.5% ± 6.8% vs 8.3% ± 4.6%, P = .014; ❚Figure 4C❚. No significant difference in MO2% was observed in bone marrow specimens ❚Figure 4D❚.
MO1% and MO3% in Differentiating CMML vs Non-CMML + Non-aCML Cases
If the MO1% cutoff value of 94% suggested by Selimoglu-Buet et al 2 was used, six of 26 CMML cases and four of 64 non-CMML + non-aCML would have been C ❚Figure 2❚ (cont) C, Representative CMML bone marrow specimen.
misclassified (overall sensitivity = 77% [88% for peripheral blood specimens, 60% for bone marrow]; overall specificity = 94% [94% for peripheral blood, 92% for bone marrow]). To compare MO3% to MO1% in differentiating CMML from non-CMML + non-aCML cases, ROC curve analyses were performed. For blood specimens, the area under the curve (AUC) was 0.881 for MO1% and 0.995 for MO3% (P = .12 for MO1% vs MO3% at differentiating CMML) and optimal cutoff values of MO1% greater than 95.1% (sensitivity, 88%; specificity, 96%) and MO3% less than 1.13% (sensitivity, 100%; specificity, 96%) were determined ❚Figure 5A❚, ❚Figure 5B❚, and ❚Figure 5C❚. ROC curve analysis of the bone marrow specimens showed similar results (AUC for MO1%, 0.829 vs AUC for MO3%, 0.992; P = .08) with optimal cutoff values of 90.3% for MO1% (sensitivity, 80%; specificity, 83%) and 2.42% for MO3% (sensitivity, 100%; specificity, 92%) ❚Figure 5D❚, ❚Figure 5E❚, and ❚Figure 5F❚.
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❚Figure 3❚ Classical monocyte percentages. A, Percentage of classical monocytes (MO1%) in chronic myelomonocytic leukemia (CMML) and non-CMML + nonatypical chronic myeloid leukemia (aCML) blood specimens. B, MO1% in CMML, aCML, and non-CMML + non-aCML bone marrow specimens. A and B, boxes represent the 25th and 75th percentiles, whiskers cap the 10th and 90th percentiles, and horizontal lines within boxes the median. Individual values outside the 10th and 90th percentiles are represented by black circles. *P < .05 between that group and the CMML group; # P < .1. C, Histogram of peripheral blood and bone marrow CMML cases that clearly illustrates a subset (the boxed circles) in both blood (2/16) and bone marrow (2/10) that have a markedly lower MO1% compared to the other CMML cases. AML, acute myeloid leukemia; B/T, B cell/ T cell; MPN, myeloproliferative neoplasm; Tx, treatment.
Discussion
We show that quantification of MO3% is a highly reliable diagnostic test for CMML in the routine clinical setting. It can be performed on both blood and bone marrow specimens with a limited number of monocyte events and so will be applicable even for specimens, particularly bone marrow specimens, with a relatively low monocyte percentage due to an abundance of other cell types in the specimen. The paradigm of using an MO1% of greater than 94% as a diagnostic marker for CMML established by Selimoglu-Buet et al 2 
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❚Figure 5❚ Receiver operator characteristic (ROC) curve analyses. A, ROC curve analyses of classical monocytes (MO1%) and nonclassical monocytes (MO3%) as a diagnostic marker for chronic myelomonocytic leukemia (CMML) in blood specimens. B, Histogram of CMML vs non-CMML + nonatypical chronic myeloid leukemia (aCML) blood specimens with the optimal cutoff value of MO1% >95.1% as a diagnostic marker for CMML. C, Histogram of CMML vs non-CMML + non-aCML blood specimens with the optimal cutoff value of MO3% <1.13% as a diagnostic marker for CMML. D, ROC curve analyses of MO1% and MO3% as a diagnostic marker for CMML in bone marrow specimens. E, Histogram of CMML vs non-CMML + non-aCML bone marrow specimens with the optimal cutoff value of MO1% >90.3% as a diagnostic marker for CMML. F, Histogram of CMML vs non-CMML + non-aCML bone marrow specimens with the optimal cutoff value of MO3% <2.42% as a diagnostic marker for CMML.
confirm here using a modified protocol that is more conducive to the clinical setting. However, while the original report showed relatively high sensitivity (approximately 91%), our study showed a greater percentage of false negatives (overall sensitivity of 77% [88% for blood, 60% for bone marrow] utilizing the >94% cutoff). Importantly, these false negatives were predominantly a subset of CMML cases with an MO1% of considerably less than 94% ( Figure 3C ) and not borderline cases that could be accounted for by having a slightly lower cutoff value. There also appears to be a similar subset of CMML cases in the Selimoglu-Buet article. 2 In our study, this subset of CMML cases did not show any particular commonalities in terms of clinical features, immunophenotype, and/or molecular findings. As sensitivity is the more important factor in a screening test, 7 this led us to investigate if the other monocyte subsets (known to be decreased in CMML 2 ) could also be of use in the diagnosis of CMML. We found that while both MO2% and MO3% are decreased in CMML, MO3% was much better at differentiating between CMML and non-CMML + non-aCML. In fact, in our hands, MO3% is as least as good for a diagnostic marker of CMML as MO1%, showing a sensitivity of 100% and a specificity of 96% in peripheral blood cases. Moreover, with bone marrow-specific cutoff values, MO3% shows similar sensitivity and specificity with bone marrow cases (92% and 100%, respectively), while MO1% is not as reliable (sensitivity, 80%; specificity, 83%).
While the protocol established by Selimoglu-Buet et al 2 has been shown to be extremely robust in differentiating CMML cases, the collection of 50,000 events in the monocyte gate has limited use in the everyday clinical setting, particularly in the context of a screening test. As most standard flow cytometry panels have stopping parameters of 50,000 to 100,000 total events, the collection of 50,000 monocytic events would necessitate having a separate stopping parameter for the analysis of monocytes and might not be optimal in terms of time efficiency. Here, we show that the collection of 50,000 total events can be utilized with similar efficacy when paired with the use of lymphocyte CD16 expression as the determination for the CD16 ± cutoff. We feel this use of a definitive cutoff has several advantages, the most important being that it limits interoperator variability, an important factor when dealing with a clinical screening test in which the gating will often be done by medical technicians and not flow cytometry research experts. Furthermore, this methodology can be implemented into large flow cytometry panels without the need for having separate stopping parameters for the analysis of monocytes, allowing for both faster work flow and the ability to retrospectively focus on monocytes if needed.
Perhaps reflecting shared pathogenetic mechanisms, MO1% or MO3% did not differentiate CMML from the three aCML cases. CMML and aCML share certain common genetic abnormalities, including trisomy 8 and mutations in SETBP1. 1 Moreover, while statistical modeling showed that CMML and aCML are distinct entities that can be distinguished clinically, 8 they are often differentiated from each other solely by the monocyte count in relation to the overall leukocyte count and studies on the two diseases are limited by aCML being such a rare disease. 1 It has been postulated that the aberrant monocyte phenotype in CMML is at least partly due to the effects of mediators released from dysplastic granulocytes.
9 Thus, it is quite possible that the similarity in monocyte subset distribution may reflect a shared or similar pathogenic mechanism. Future studies are needed to further characterize monocyte subset distribution in aCML.
In conclusion, this report shows that quantification of MO3% can be used in routine clinical practice as a diagnostic marker of CMML in both blood and bone marrow specimens.
